Indications
Reduce the risk of preterm birth in women
Indicated for reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
Indicated for prevention of preterm labor in a singleton pregnancy for patients aged 16 years or older who have a history of spontaneous preterm birth
Dosage And Administration
Administer intramuscularly at a dose of 500 mg or 250 mg once weekly. Begin treatment between 16 weeks, 0 days and 20 weeks, 6 days of gestation. Continue administration once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first.
Administration-
Clean the ampoule top with an alcohol swab before use.
Draw up 1 ml of drug into a 2 ml syringe.
After preparing the skin, inject in the upper outer quadrant of the gluteus maximus. The solution is viscous and oily. Slow injection (over one minute or longer) is recommended.
Applying pressure to the injection site may minimize bruising and swelling.
Side Effects
Most Common: Injection site reactions (pain, swelling, pruritus, nodule), Hives, Itching, nausea, and diarrhea. Call your doctor if you get any of the symptoms below:
Blood clots Symptoms: Leg swelling, Redness in your leg, a spot on your leg that is warm to touch, Leg pain that worsens when you bend your foot.
Allergic reactions: Hives, Itching, Swelling of the face.
Precautions And Warnings
Thromboembolic disorders: Discontinue if thrombosis or thromboembolism occurs. Allergic reactions: Consider discontinuing if allergic reactions occur.
Decreased glucose tolerance: Monitor pre-diabetic and diabetic women receiving Hydroxyprogesterone Caproate.
Fluid retention: Monitor women with conditions that may be affected by fluid retention, such as pre-eclampsia, epilepsy, cardiac or renal dysfunction.
Depression: Monitor women with a history of clinical depression; discontinue Hydroxyprogesterone Caproate if depression recurs.
Jaundice: Carefully monitor women who develop jaundice while receiving Hydroxyprogesterone Caproate and consider whether the benefit of use warrants continuation.
Hypertension: Carefully monitor women who develop hypertension while receiving Hydroxyprogesterone Caproate and consider whether the benefit of use warrants continuation.
Pregnancy And Lactation
Pregnancy: Category B. No adequate and well-controlled studies in women during first trimester of pregnancy. Teratogenic risks to infants following in utero exposure to the drug not demonstrated in a study of pregnant women receiving the drug during their second and third trimesters, as well as in a follow-up safety study of their infants. Not intended to stop active preterm labor; effect of drug for this use unknown.
Lactation: Detectable amounts of progestins identified in the breast milk of women receiving progestins. No adverse effects of progestins on breastfeeding performance or on health, growth, or development of infants, Discontinue drug at 37 weeks of gestation or upon delivery.